Abstract
During the last decade, the role of B cells in the pathogenesis of autoimmune diseases has been highlighted. Treatment selectively targeting B cells has been made available through the development of (humanized) monoclonal antibodies. Rituximab (anti-CD20) depletes mature B cells and has been successfully used in several systemic autoimmune diseases. At present, only one randomized controlled trial has been performed, and more trials are planned. Additionally, other B-cell targeting monoclonals, such as epratuzumab (anti-CD22) and belimumab (anti-BLyS/BAFF) are being tested. In this article, the presently published (open) studies using these monoclonal therapies are reviewed and future perspectives in this area are discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
